c CI includes values suggesting no effect and values suggesting either bene t or harm. d Pooled analysis of Schulman et al20 (RE-COVER I) and Schulman et al24 (RE-COVER II) performed by Schulman et al.24 *2. In patients with DVT of the leg or PE and no cancer, as long-term ( rst 3 months) anticoagulant therapy, we suggest dabigatran, rivaroxaban, apix- aban, or edoxaban over vitamin K antagonist (VKA) therapy (all Grade 2B). For patients with DVT of the leg or PE and no cancer who are not treated with dabigatran, rivaroxaban, apixaban, or edoxaban, we suggest VKA therapy over LMWH (Grade 2C). Remarks: Initial parenteral anticoagulation is given before dabigatran and edoxaban, is not given before rivaroxaban and apixaban, and is overlapped with VKA therapy. See text for factors that in uence choice of therapy. In patients with VTE and cancer ( cancer-associated thrombosis ), as noted earlier in this section, we still suggest LMWH over VKA. In patients with VTE and cancer who are not treated with LMWH, we do not have TABLE 3 ] Summary of Findings: Rivaroxaban vs LMWH and VKA for Acute and Long-Term Treatment of VTEa,b Outcomes No. of Participants (Studies) Follow-up Quality of the Evidence (GRADE) Relative Effect Anticipated absolute effects Risk with LMWH and VKA Risk difference with Rivaroxaban (95% CI) All-cause mortality Moderatec because of imprecision (from 6 fewer to 6 more) Recurrent VTE 8,281 Moderatec because of imprecision (from 7 fewer to 5 more) Major bleeding 8,246 High (from 3 fewer to 11 fewer) The basis for the assumed risk (eg, the median control group risk across studies) is provided in the footnotes. 